BioMarin Pharmaceutical Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +36.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.79 | $0.90 | +13.9% | Beat | |
| Q1 FY26 | $0.78 | $0.58 | -25.6% | Miss | Q1 FY26 call |
| Q4 FY25 | not reported | $0.28 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | not reported | $-0.08 | not reported | not reported | |
| Q2 FY25 | $0.80 | $1.25 | +56.3% | Beat | Q2 FY25 call |
| Q1 FY25 | $0.73 | $0.98 | +34.3% | Beat | |
| Q4 FY24 | $0.55 | $0.72 | +30.9% | Beat | |
| Q3 FY24 | $0.57 | $0.74 | +29.8% | Beat | |
| Q2 FY24 | $0.38 | $0.77 | +102.6% | Beat | |
| Q1 FY24 | $0.37 | $0.49 | +32.4% | Beat | |
| Q4 FY23 | $0.24 | $0.26 | +8.3% | Beat | |
| Q3 FY23 | $0.28 | $0.26 | -7.1% | Miss |
Back to BMRN overview · BMRN holders · BMRN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.